Identification of key genes unique to the luminal A and basal-like breast cancer subtypes via bioinformatic analysis

Jia, Rong; Li, Zhongxian; Liang, Wei; Ji, Yucheng; Weng, Yujie; Liang, Ying; Ning, Pengfei

doi:10.21203/rs.3.rs-28637/v2

Cited by 3 publications

(5 citation statements)

References 25 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miRNAs have a significant effect on the early diagnosis and prognostic evaluation of BC and on reversing the drug resistance of cancers [14]. All kinds of miRNAs have abnormal expression in BC [15,16], and these maladjusted miRNAs play an antitumour or carcinogenic role in the disease and are involved in its pathological process [17,18]. There is abnormal expression of miR-92b-3p in colorectal cancer [19,20] and oesophageal squamous cell carcinoma [21].…”

Section: Discussionmentioning

confidence: 99%

Expression levels and clinical values of miR-92b-3p in breast cancer

Miao

Wang

et al. 2021

World J Surg Onc

View full text Add to dashboard Cite

Background miR-92b is a carcinogenic miRNA that has great potential as a biomarker for disease prognosis, diagnosis, and treatment in the clinic. It is of great significance to analyse the relationship between miR-92b and the clinicopathological characteristics of cancer patients. This paper aimed to investigate the expression levels and clinical values of miR-92b-3p in breast cancer (BC). Methods Altogether, 112 female BC patients who were treated in our hospital were included as a study group, and 108 healthy women who came to our hospital for physical examinations were included as a control group. miR-92b-3p expression in the serum of subjects in both groups was detected by fluorescence quantitative PCR (RT-PCR) to analyse the correlation of this miRNA with the patients’ pathological features and prognoses. The diagnostic value of miR-92b-3p expression for BC was analysed by plotting a receiver operating characteristic (ROC) curve. Results miR-92b-3p expression was remarkably higher in the study group (P < 0.05), and its area under the curve (AUC) for detecting BC was 0.88. The expression was correlated with the tumour size, degree of differentiation, TNM staging, and lymphatic metastasis (P < 0.05). miR-92b-3p was significantly positively correlated with the TNM staging (r = 0.40, P < 0.05), was significantly negatively correlated with the degree of differentiation of the breast cancer cells (r = − 0.35, P < 0.05), and was significantly positively correlated with the expression of carbohydrate antigen 125 (CA125) (r = 0.39, P < 0.05). The overall survival rate (OSR) of the 99 patients who had follow-up was 73.74%. The survival status was remarkably better in the low expression group (P < 0.05). miR-92b-3p expression was remarkably higher in the death group (P < 0.05). The AUC of miR-92b-3p alone in the death and survival groups was 0.76. Conclusion miR-92b-3p expression obviously rises in the serum of BC patients and is closely related to the clinical staging, degree of differentiation, and CA125 in BC, so the detection of this miRNA is of great significance to the diagnosis and prognostic evaluation of BC. This miRNA can be used as a potential biomarker for the diagnosis and prognosis of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression levels and clinical values of miR-92b-3p in breast cancer

Miao

Wang

et al. 2021

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…High expression of KIF18A exhibited prognostic relevance in ER-positive breast cancer, which can be used as marker to monitor the benefit of endocrine therapy. 46–48…”

Section: Major Genes and Signaling Pathways In Breast Cancersmentioning

confidence: 99%

“…High expression of KIF18A exhibited prognostic relevance in ERpositive breast cancer, which can be used as marker to monitor the benet of endocrine therapy. [46][47][48] Forkhead box protein 3 (FOXP3) is expressed both mRNA and protein levels in nucleus of epithelial cells in breast. Cancer cells can dysregulate FOXP3 expression.…”

Section: Major Genes and Signaling Pathways In Breast Cancersmentioning

confidence: 99%

“…CDC7 is used as prognostic marker and therapeutic target for TNBC. 46 TNBC involves genes correlated with DNA damage repair (DDR) and phosphatidylinositol 3-kinase (PI3K). This pathway ensues due to the loss of negative regulators, PTEN or INPP4B or activating mutations PIK3CA accompanying other genes in the PI3K/TOR signaling system.…”

Section: Major Genes and Signaling Pathways In Breast Cancersmentioning

confidence: 99%

See 1 more Smart Citation

Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics

Subhan

2022

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…We used 4 gene signatures to score the individual patient samples to characterize their luminal, basal, epithelial and mesenchymal characteristics. The gene lists for the luminal and basal signature were obtained from a cumulative list of genes (Supplementary Table S4) listed from previously published reports (13)(14)(15)(16)(17) and the gene lists for the epithelial and mesenchymal programs were obtained from Tan et al, EMBO Mol. Med.…”

Section: Computational Analysis For Correlation With E/m Hybrid Scorementioning

confidence: 99%

Acquisition of hybrid E/M phenotype associated with increased migration, drug resistance and stemness is mediated by reduced miR-18a levels in ER-negative breast cancer

Nair

Apoorva

Chandrakala

et al. 2022

Preprint

View full text Add to dashboard Cite

The complexity of the ER-negative subtype of breast cancer arises due to the heterogeneous nature of the disease rendering them more aggressive and this poses a challenge to effective treatment and eventually the prognosis of the patients. We have explored the miRNA regulation of altered molecular signatures and the effect on tumour progression in ER-negative breast cancer. Using breast tumour specimens, gene expression data from public datasets and in-vitro and in-vivo model systems we have shown that low-levels of miR-18a in ER-negative tumours drives enrichment of hybrid Epithelial/Mesenchymal (E/M) cells with luminal attributes. On inhibition of miR-18a in ER-negative breast cancer cell lines, the cells showed traits of increased migration, stemness and drug-resistance. miR-18a/low tumours were also associated with increased expression of genes associated with EMT, stemness, drug resistance and immune-suppression. Further analysis of the miR-18a targets pointed out at a possible HIF-1α mediated signalling in these tumours. HIF-1α inhibition reduced the enrichment of the hybrid E/M cells and decreased the migratory ability of miR-18a/low cells. Our study reports for the first time a dual role of miR-18a in breast cancer that is subtype specific based on hormone receptor expression and a novel association of low miR-18a levels and enrichment of hybrid E/M cells. The results highlight the possibility of stratifying the ER-negative disease into clinically relevant groups by analysing epigenetic signatures.

show abstract

Identification of key genes unique to the luminal A and basal-like breast cancer subtypes via bioinformatic analysis

Cited by 3 publications

References 25 publications

Expression levels and clinical values of miR-92b-3p in breast cancer

Expression levels and clinical values of miR-92b-3p in breast cancer

Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics

Acquisition of hybrid E/M phenotype associated with increased migration, drug resistance and stemness is mediated by reduced miR-18a levels in ER-negative breast cancer

Contact Info

Product

Resources

About